Defense World
16 Aug 2026, 07:53 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Corcept Therapeutics reported Q2 earnings of $0.36 per share and revenue of $256.15 million, significantly beating consensus estimates of $0.02 EPS and $221.15 million in revenue. — Substantial beats on both top and bottom lines typically trigger positive price action and signal operational strength.
+0.60Company insiders have sold 402,876 shares totaling over $35 million in the last 90 days, including a sale of 80,000 shares (an 83% reduction in holding) by CFO Atabak Mokari. — Heavy insider selling, particularly by the CFO, is often viewed as a bearish signal regarding the stock's near-term valuation.
-0.40HC Wainwright significantly raised its price target for CORT from $95.00 to $165.00 with a 'buy' rating. — A major price target increase provides a bullish catalyst and suggests significant untapped upside potential.
+0.30Continue reading
6 related stories
Search tags
Institutional investors, including Handelsbanken Fonder AB, GAMMA Investing LLC, and Pacer Advisors Inc., increased their positions in the second quarter. — Increased institutional accumulation indicates professional confidence in the company's trajectory.
+0.20Which stocks this story touches
The company beat EPS and revenue estimates, saw significant institutional buying, and received multiple analyst upgrades, though this is slightly offset by insider selling.
Truist Financial issued a 'strong-buy' rating for Corcept Therapeutics, reflecting positive analyst conviction.
UBS Group provided a positive target price for Corcept Therapeutics.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
53m ago
